ES2121078T3 - Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana. - Google Patents

Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana.

Info

Publication number
ES2121078T3
ES2121078T3 ES93905927T ES93905927T ES2121078T3 ES 2121078 T3 ES2121078 T3 ES 2121078T3 ES 93905927 T ES93905927 T ES 93905927T ES 93905927 T ES93905927 T ES 93905927T ES 2121078 T3 ES2121078 T3 ES 2121078T3
Authority
ES
Spain
Prior art keywords
pct
monoclonal antibodies
human
cloning
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93905927T
Other languages
English (en)
Inventor
John S Abrams
Barbara Dalie
Hung V Le
Kenneth Miller
Nicholas J Murgolo
Hanh Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2121078T3 publication Critical patent/ES2121078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTAN ANTICUERPOS MONOCLONALES QUE SON ESPECIFICOS A LA INTERLEUQUINA-4 HUMANA. TAMBIEN SE PRESENTAN LOS ADNS COMPLEMENTARIOS QUE CODIFICAN LAS REGIONES VARIABLES DE CADENA LIGERA Y PESADA DE TALES ANTICUERPOS MONOCLONALES Y LAS REGIONES DE DETERMINACION DE LA COMPLEMENTARIEDAD DE TALES ADNS; Y LOS KITS Y METODOS PARA DETECTAR, MEDIR E INMUNOPURIFICAR LA INTERLEUQUINA-4 HUMANA Y PARA BLOQUEAR LA ACTIVIDAD BIOLOGICA DE LA INTERLEUQUINA-4 HUMANA.
ES93905927T 1992-02-19 1993-02-18 Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana. Expired - Lifetime ES2121078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84165992A 1992-02-19 1992-02-19

Publications (1)

Publication Number Publication Date
ES2121078T3 true ES2121078T3 (es) 1998-11-16

Family

ID=25285411

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93905927T Expired - Lifetime ES2121078T3 (es) 1992-02-19 1993-02-18 Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana.

Country Status (18)

Country Link
US (2) US5863537A (es)
EP (1) EP0627002B1 (es)
JP (1) JPH07502901A (es)
KR (1) KR0158240B1 (es)
CN (1) CN1076966A (es)
AT (1) ATE171472T1 (es)
AU (1) AU684041B2 (es)
CA (1) CA2130436C (es)
DE (1) DE69321218T2 (es)
DK (1) DK0627002T3 (es)
ES (1) ES2121078T3 (es)
HK (1) HK1008831A1 (es)
IL (1) IL104782A0 (es)
MX (1) MX9300913A (es)
NZ (1) NZ249677A (es)
SG (1) SG52215A1 (es)
WO (1) WO1993017106A1 (es)
ZA (1) ZA931148B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017106A1 (en) * 1992-02-19 1993-09-02 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
BR9407575A (pt) * 1993-09-07 1996-07-16 Smithkline Beecham Corp Recombinaçao il4 de anticorpos uteis no tratamento de desordens do il4
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
AU2004202605B2 (en) 1998-07-13 2007-10-25 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1173790A2 (en) * 1999-03-01 2002-01-23 Boston Innovative Optics, Inc. System and method for increasing the depth of focus of the human eye
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
NZ584715A (en) 2002-07-15 2011-12-22 Univ Texas Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
WO2004044161A2 (en) * 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
NZ540562A (en) 2002-11-26 2008-04-30 Pdl Biopharma Inc Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
EP1594956A4 (en) 2003-02-03 2007-08-01 Fraunhofer Usa Inc SYSTEM FOR EXPRESSION OF GENES IN PLANTS
US20050002930A1 (en) * 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
CA2526720C (en) 2003-05-22 2013-10-22 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US7628810B2 (en) * 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
US20050046794A1 (en) * 2003-06-17 2005-03-03 Silvestrini Thomas A. Method and apparatus for aligning a mask with the visual axis of an eye
WO2005081905A2 (en) * 2004-02-20 2005-09-09 Fraunhofer Usa Inc. Systems and methods for clonal expression in plants
CA2560508A1 (en) * 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
US7976577B2 (en) 2005-04-14 2011-07-12 Acufocus, Inc. Corneal optic formed of degradation resistant polymer
EP1919504B1 (en) * 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
BRPI0707779B8 (pt) * 2006-02-13 2021-05-25 Fraunhofer Usa Inc antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
JP2009526526A (ja) * 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗原、ワクチン組成物、および関連する方法
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
BRPI0810865A2 (pt) * 2007-04-28 2017-05-09 Fraunhofer Usa Inc antígenos de tripanossoma, composições vacinais, e métodos relacionados
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CA2694644A1 (en) * 2007-07-27 2009-02-05 Vanitha Ramakrishnan Pharmaceutical combinations
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
AU2010282311B2 (en) 2009-08-13 2015-08-13 Acufocus, Inc. Masked intraocular implants and lenses
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
USD656526S1 (en) 2009-11-10 2012-03-27 Acufocus, Inc. Ocular mask
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
WO2013082545A1 (en) 2011-12-02 2013-06-06 Acufocus, Inc. Ocular mask having selective spectral transmission
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CN104870423A (zh) 2012-11-16 2015-08-26 加利福尼亚大学董事会 用于蛋白质化学修饰的pictet-spengler连接反应
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN103421747B (zh) * 2013-09-09 2015-01-07 扬州大学 分泌牛il-4单克隆抗体的杂交瘤细胞株、其单克隆抗体及其应用
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2015187428A1 (en) 2014-06-06 2015-12-10 Redwood Bioscience, Inc. Anti-her2 antibody-maytansine conjugates and methods of use thereof
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US10316094B2 (en) 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
WO2016081455A1 (en) 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
EP3370764A4 (en) 2015-11-05 2019-07-17 The Regents of The University of California CELLS MARKED BY LIPID CONJUGATES AND METHODS OF USING THE SAME
AU2016354009B2 (en) 2015-11-09 2021-05-20 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
DK3468998T3 (en) 2016-06-09 2022-03-07 Pelican Therapeutics Inc Anti-tnfrsf25-antistoffer
US10240581B2 (en) 2017-02-08 2019-03-26 General Electric Company System and method for controlling pitch angle of a wind turbine rotor blade
CN113101364B (zh) * 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
IL89489A0 (en) * 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9105292D0 (en) * 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
WO1993017106A1 (en) * 1992-02-19 1993-09-02 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4

Also Published As

Publication number Publication date
DE69321218D1 (de) 1998-10-29
JPH07502901A (ja) 1995-03-30
ZA931148B (en) 1993-08-18
KR0158240B1 (ko) 1998-11-16
MX9300913A (es) 1994-08-31
AU684041B2 (en) 1997-12-04
US5863537A (en) 1999-01-26
CA2130436C (en) 2001-04-10
EP0627002B1 (en) 1998-09-23
AU3666293A (en) 1993-09-13
WO1993017106A1 (en) 1993-09-02
CN1076966A (zh) 1993-10-06
NZ249677A (en) 1996-08-27
SG52215A1 (en) 1998-09-28
ATE171472T1 (de) 1998-10-15
EP0627002A1 (en) 1994-12-07
DE69321218T2 (de) 1999-02-18
US5770403A (en) 1998-06-23
HK1008831A1 (en) 1999-05-21
KR950700414A (ko) 1995-01-16
IL104782A0 (en) 1993-06-10
CA2130436A1 (en) 1993-09-02
DK0627002T3 (da) 1999-06-14

Similar Documents

Publication Publication Date Title
ES2121078T3 (es) Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana.
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
DK0668924T3 (da) Humaniserede antistoffer mod Fc-receptorer for immunoglobulin G på humane mononukleare fagocytter
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
DE69322860D1 (de) Antikörper gegen alpha v beta 3 integrin
DE69229278D1 (de) Humanisierter b-b10, ein anti-il-2-rezeptor-antikörper
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
FI960567A (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
FI944509A (fi) Interferonireseptorin vastaisia monoklonaalisia vasta-aineita, joilla on neutralisoivaa aktiivisuutta tyypin I interferonia vastaan
ES2121358T3 (es) Anticuerpos monoclonales humanizados contra interleuquina-4 humana.
FR2664702B1 (fr) Procede de reduction d'interferences dans un dosage par fluorescence.
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
ATE188746T1 (de) Adeno-assozierter virus - dessen diagnostischen anwendung für frühe abtreibung
DE69334036D1 (de) Hybridom und humanisierter monoklonaler anti-kc-4-antikörper, dafür kodierende dnas und rnas, kit und diagnostische verfahren
DE3775182D1 (de) Monoklonale antikoerper gegen menschliche ige-rezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper.
HUP9903273A3 (en) Anti-human mp52 monoclonal antibody

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 627002

Country of ref document: ES